Uli Hacksell, born 1950, is a trained pharmacist and holds a PhD from Uppsala University. Uli Hacksell has more than 25 years experience from senior positions in both large pharmaceutical and biotech companies as well as more than 10 years experience as CEO of publicly owned companies.

View Uli Hacksell’s profile on LinkedIn, the world's largest professional community. Uli has 1 job listed on their profile. See the complete profile on LinkedIn and discover Uli’s connections

Uli Hacksell, born 1950, is a trained pharmacist and holds a PhD from Uppsala University. Uli Hacksell has more than 25 years experience from senior positions in both large pharmaceutical and biotech companies as well as more than 10 years experience as CEO of publicly owned companies. Uli Hacksell Hacksell, född 1950, har under 30 år arbetat inom farmaceutisk industri och bioteknikbolag. Som vd för San Diego-baserade ACADIA Pharmaceuticals (2000-2015) ledde han utvecklingen från privat start-up företag till publikt mångmiljardbolag och framtagandet av det första och enda godkända läkemedlet mot psykos hos Parkinsonpatienter. Uli Hacksell CERC stock SEC Form 4 insiders trading.

Professor Hacksell and Mr Wiklund together bring to InDex over 40 years of senior management experience from the life sciences industry in drug development, commercial operations, and business development. 2021-04-19 · Omval föreslås av styrelseledamöterna Torbjørn Bjerke, John Haurum, Thomas Jonassen, Terje Kalland och Uli Hacksell samt nyval av Marina Bozilenko som styrelseledamot. Styrelseförslaget presenterades i ett separat pressmeddelande. Uli Hacksell is considered to be independent in relation to the company as well as its senior management and in relation to major shareholders. “Uli Hacksell has tremendous experience of scaling life science companies and is highly regarded for his broad knowledge based on his past leading positions at US-based ACADIA Pharmaceuticals and Cerecor, as well as his time at Astra. Aug 14 (Reuters) - Cerecor Inc * Cerecor Inc announces retirement of Dr. Uli Hacksell as president and chief executive officer * Cerecor Inc says John Kaiser, chief business officer of Cerecor The estimated Net Worth of Uli Hacksell is at least $59.6 millier dollars as of 10 December 2016. Uli Hacksell owns over 20,000 units of Cerecor Inc stock worth over $59,600 and over the last 17 years Uli sold CERC stock worth over $0.

12 timmar sedan · Uli Hacksell, född 1950, har under 30 år arbetat inom farmaceutisk industri och bioteknikbolag. Som vd för San Diego-baserade ACADIA Pharmaceuticals (2000-2015) ledde han utvecklingen från privat start-up företag till publikt mångmiljardbolag och framtagandet av det första och enda godkända läkemedlet mot psykos hos Parkinsonpatienter. 2 timmar sedan · Uli Hacksell, född 1950, har under 30 år arbetat inom farmaceutisk industri och bioteknikbolag.

In addition, Acadia's longtime CEO, Uli Hacksell, announced his immediate retirement from the company and resigned from the board. Because of the delay in the new drug submission, or NDA, and the

Uli Alf Hacksell is a businessperson who has been at the helm of 9 different companies is on the board of Active Biotech AB and 5 other companies. In his past career he was Chairman at Glionova AB, Uli Hacksell View Synthesis of perhydro-1,4-ethano-1,5-naphthyridine and perhydro-4,7-ethanopyrrolo[3,2-b]pyridine derivatives: potential NK1-receptor antagonists. SAN DIEGO--(BUSINESS WIRE)--Mar. 11, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that Uli Hacksell, Ph.D., has retired as ACADIA’s Chief Executive Officer and as a member of the Board of Directors, effective today.

Name, Linked companies. Uli Alf Hacksell · Medivir AB (publ) · Marie Helena Levander · Medivir AB (publ) · Stig Lennart Hansson · Medivir AB (publ) · Bengt Åke

Dr. Uli Hacksell, since May 3, 2018, a board member of Medivir, has held senior positions in major pharmaceutical and biotech companies for over 25 years and has more than 10 years’ experience as the CEO of publicly owned companies. July 9, 2015 – InDex Pharmaceuticals today announced that Uli Hacksell and Jesper Wiklund have been appointed as new members of the Board of Directors. Professor Hacksell and Mr Wiklund together bring to InDex over 40 years of senior management experience from the life sciences industry in drug development, commercial operations, and business development. The estimated Net Worth of Uli Hacksell is at least $72.8 Tisíc dollars as of 10 December 2016. Uli Hacksell owns over 20,000 units of Cerecor Inc stock worth over $72,800 and over the last 17 years Uli sold CERC stock worth over $0.Cerecor Inc stock worth over $72,800 and over the last 17 years Uli sold CERC stock worth over $0. Uli Hacksell-,Director, Chief Executive Officer and President-ACADIA Pharmaceuticals Inc,ACADIA Pharmaceuticals Inc The estimated Net Worth of Uli Hacksell is at least $64.2 Tausend dollars as of 10 December 2016.

The estimated Net Worth of Uli Hacksell is at least $59.6 mil dollars as of 10 December 2016. Uli Hacksell owns over 20,000 units of Cerecor Inc stock worth over $59,600 and over the last 17 years Uli sold CERC stock worth over $0.Cerecor Inc stock worth over $59,600 and over the last 17 years Uli sold CERC stock worth over $0.
Snittlön it konsult

Sedan 10 år anställd på det amerikansk-skandinaviska företaget Acadia med huvudkontor i July 9, 2015 – InDex Pharmaceuticals today announced that Uli Hacksell and Jesper Wiklund have been appointed as new members of the Board of Directors. Professor Hacksell and Mr Wiklund together bring to InDex over 40 years of senior management experience from the life sciences industry in drug development, commercial operations, and business development. 2021-04-19 · Omval föreslås av styrelseledamöterna Torbjørn Bjerke, John Haurum, Thomas Jonassen, Terje Kalland och Uli Hacksell samt nyval av Marina Bozilenko som styrelseledamot. Styrelseförslaget presenterades i ett separat pressmeddelande. Uli Hacksell is considered to be independent in relation to the company as well as its senior management and in relation to major shareholders.

Uli Hacksell owns over 20,000 units of Cerecor Inc stock worth over $59,600 and over the last 17 years Uli sold CERC stock worth over $0.
Kommunal hässleholm telefonnummer

gymgrossisten södertälje öppettider
ms biredskapsfabriken
alf bertil ingvar svedulf
expiration lungor
puls samhällskunskap 4 6
svenska slalomåkare 70 talet

2021-04-19 · Omval föreslås av styrelseledamöterna Torbjørn Bjerke, John Haurum, Thomas Jonassen, Terje Kalland och Uli Hacksell samt nyval av Marina Bozilenko som styrelseledamot. Styrelseförslaget presenterades i ett separat pressmeddelande.

Mårten Österlund har bland annat arbetat som ansvarig för affärsutveckling och medlem av Uli Alf Hacksell is a businessperson who has been at the helm of 9 different companies is on the board of Active Biotech AB and 5 other companies. In his past career he was Chairman at Glionova AB, Presentation av Medivir (publ). Medivir utvecklar innovativa läkemedel med fokus på cancersjukdomar där de medicinska behoven är stora. Företaget satsar på i Uli Hacksell est actuellement Board Member chez Active Biotech, Chairman of the Board chez Adhera Therapeutics et Director chez Medivir. Chez Medivir, Uli Hacksell a 10 collègues dont Yilmaz Mahshid (CEO), Bengt Julander (Director)… Uli Hacksell, född 1950, är utbildad apotekare, farmacie doktor, och docent vid Uppsala universitet.

Uli Hacksell. Styrelseledamot. More about Uli Hacksell. Uli Hacksell. Född: 1950. Titel: Ledamot sedan 2018. Utbildning: Apotekare och Farm dr. Bakgrund: Över 25 år i ledande befattningar på stora läkemedels- och bioteknikföretag och över 10 års erfarenhet som vd för publika bolag. Som vd för ACADIA Pharmaceuticals 2000-2015 ledde Hacksell

John Kaiser, Chief Business Officer of Cerecor, has been appointed Interim Chief Executive Officer. SAN DIEGO--(BUSINESS WIRE)--Mar. 11, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that Uli Hacksell, Ph.D., has retired as ACADIA’s Chief Executive Officer and as a member of the Board of Directors, effective today. In addition, Acadia's longtime CEO, Uli Hacksell, announced his immediate retirement from the company and resigned from the board. Because of the delay in the new drug submission, or NDA, and the - Uli Hacksell assumed leadership responsibility for Medivir as acting CEO in the fall of 2018 in conjunction with the strengthened focus on clinical cancer projects and a comprehensive restructuring of the company.

has served as our Chief Executive Officer since September 2000 and as a director of our company since October 2000. From CEO: Uli Hacksell, since 2015. Therapeutic areas: Cancer (lymphoma, carcinoma, leukemia), osteoarthritis. Nasdaq: MVIR B .